ACC Action Center
Welcome to the ACC Action Center, bringing you the latest updates from the American College of Cardiology’s Annual Scientific Session & Expo, hosted in partnership with the World Congress of Cardiology. This collection will highlight emerging clinical data and explore the latest practice-changing advances in the field of cardiology.
16-30 of 67
Secondary prevention strategy led by nurses reduces MACE risk after an ACS
ACC Action CenterSecondary prevention strategy led by nurses reduces MACE risk after an ACS
Secondary prevention post-ACS: a nurse-led intervention strategy
ACC Action CenterSecondary prevention post-ACS: a nurse-led intervention strategy
Intensive medical therapy does not reduce MACE risk in women with INOCA
ACC Action CenterIntensive medical therapy does not reduce MACE risk in women with INOCA
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
CardiologyAnalysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
CardiologyEffect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
CardiologyKidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
- advertisement
Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
CardiologyMode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
CME/CEFAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
NYHA FC and Finerenone Response: Clinical Trial Insights
CardiologyNYHA FC and Finerenone Response: Clinical Trial Insights
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
ACC Action CenterSemaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
Ticagrelor antidote restores platelet function in phase 3 study
ACC Action CenterTicagrelor antidote restores platelet function in phase 3 study
- advertisement
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
ACC Action CenterEffects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
Targeting cardiac energetics with cardiac mitotrope in nonobstructive HCM
ACC Action CenterTargeting cardiac energetics with cardiac mitotrope in nonobstructive HCM
Long-term improvements in daily steps with gamification and financial incentives in patients at risk for CV events
ACC Action CenterLong-term improvements in daily steps with gamification and financial incentives in patients at risk for CV events
